Lots to look forward to …..20 Oct 2025 08:07
Let’s cut through the noise and focus on facts: P140 isn’t just another autoimmune asset — it’s differentiated, de-risked, and potentially transformative.
1. Strategic Leadership
The appointment of Ketan Patel as NED is a sign of serious intent. His track record at JP Morgan and EdenTree brings credibility and access to capital markets. This is a step towards institutional alignment.
2. Partnering & Big Pharma Interest
IMM has confirmed it is in advanced discussions with potential partners. These talks take time, especially when dealing with a first-in-class, platform technology that spans multiple autoimmune diseases. Silence - inaction. No top-tier pharma signs on hype — they follow due diligence processes, which are clearly underway.
3. P140’s Differentiated Value Proposition
Let’s look at what sets P140 apart:
* Pan-autoimmune potential: Treats across a range of diseases. If 10% of a $100B+ autoimmune market qualifies as super-responders, this is blockbuster territory.
* No immunosuppressive side effects: A major advantage over existing therapies — leading to faster regulatory pathways and stronger market uptake.
* Precision diagnostics: A companion test identifies likely responders — reducing trial risk, accelerating development, and unlocking a second income stream. (The diagnostic market alone is valued at ~$10B.)
* Strong IP position: Patent protection extending up to 20 years — rare in late-stage biotech, offering long-term exclusivity and higher valuation multiples.
* R&D momentum: With recent senior hires and an expanding pipeline, IMM is clearly gearing up for execution.
4. Validation Will Flip the Narrative
Critics claiming “institutions won’t touch this” are speaking from emotion, not evidence. The biotech sector is full of examples where late-stage assets turned sentiment around overnight with the right data or deal. As Tim McCarthy recently stated, P140 is more valuable than any of the immunomodulation assets licensed in recent years — and those went for multi-billions.
5. Positioned for a Good Deal
Given the asset’s profile, expect a strong licensing deal. Pharma wants drugs that are:
* De-risked
* Targeted
* Scalable
* Protected by IP
P140 ticks every box.
6. Timing
Frustration over timelines is understandable — but irrelevant. Biotech moves at the pace of validation, not speculation. Deal discussions are live. That’s not PR fluff — it’s reality.
Sign In
Follow the stocks
